Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00345956
Status:
COMPLETED
Last Update Posted:
2016-10-28
First Post:
2006-06-28
Brief Title:
To Evaluate Immunogenicity Reactogenicity Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants Vietnam
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Placebo-controlled Study to Evaluate the Immunogenicity Reactogenicity and Safety of Two Doses of GSK Biologicals Oral Live Attenuated Human Rotavirus HRV Liquid Vaccine When Given to Healthy Infants in Vietnam
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide specific data on immunogenicity of GSK Biologicals HRV liquid vaccine when co-administered with the routine Expanded Program of Immunization EPI in Vietnam The study will also assess reactogenicity and safety of the HRV liquid vaccine relative to the placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None